Cargando…
Empagliflozin: a potential anticancer drug
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a highly effective and well-tolerated antidiabetic drug. In addition to hypoglycemic effects, empagliflozin has many other effects, such as being hypotensive and cardioprotective. It also has anti-inflammatory and antioxidative st...
Autores principales: | Wu, Wenwen, Wang, Yanyan, Xie, Jun, Fan, Shaohua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338413/ https://www.ncbi.nlm.nih.gov/pubmed/37436535 http://dx.doi.org/10.1007/s12672-023-00719-x |
Ejemplares similares
-
Drug eruption associated with empagliflozin
por: Yau, Kevin, et al.
Publicado: (2022) -
Anti-inflammatory potential of Empagliflozin
por: Pirklbauer, Markus
Publicado: (2021) -
Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019) -
Dihydroartemisinin: A Potential Natural Anticancer Drug
por: Dai, Xiaoshuo, et al.
Publicado: (2021) -
Empagliflozin: Novel antidiabetes and pro-cardiac drug
por: Raut, Monish S, et al.
Publicado: (2017)